Mela Sciences Inc Com (NASDAQ:MELA)

CAPS Rating: 1 out of 5

A medical device company which focuses on designing and development of a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma.

Results 1 - 20 of 43 : 1 2 3 Next »

Recs

0
Member Avatar BooDog2 (< 20) Submitted: 5/10/2013 6:58:32 AM : Outperform Start Price: $11.20 MELA Score: -114.66

Homing pigeon.

Recs

2
Member Avatar FWWright (< 20) Submitted: 6/14/2012 11:18:56 PM : Outperform Start Price: $25.50 MELA Score: -149.41

I have had skin cancer and will have more and am waiting for my dermatologist to buy a non-invasive tester so he doesn't just freeze everything off or in the worse looking ones have me make a separate appointment for removal/biopsy.

Recs

0
Member Avatar WRXkid (84.47) Submitted: 3/29/2012 2:01:49 PM : Outperform Start Price: $43.10 MELA Score: -144.79

Commercial launch of MelaFind in EU and US.

Recs

2
Member Avatar blankettegirl (29.72) Submitted: 2/21/2012 8:13:34 AM : Outperform Start Price: $43.00 MELA Score: -147.74

Well, more clinical results are in, showing that Melafind really works: http://archderm.ama-assn.org/cgi/content/full/archdermatol.2011.3388. As a result, I'm in too.

Recs

0
Member Avatar lud6 (< 20) Submitted: 11/2/2011 10:42:14 AM : Outperform Start Price: $55.90 MELA Score: -164.01

With the good news from Europe and the baby step taken by the FDA, the outlook is good that this undervalued stock finally get its due.

Recs

1
Member Avatar MChoice (< 20) Submitted: 10/6/2011 5:58:25 PM : Outperform Start Price: $56.70 MELA Score: -173.67

This stock will outperform the market through Q4 2011 and for many years to come. MELA has a device for which the very doctors that it was designed for have admitted a need. The device works, and all of the data from the trial that the FDA themselves designed with MELA confirms this. The data has been continually misinterpreted by the FDA, as well as by analysts and reporters. The labeling stipulations in the FDA approvable letter have also been shortsightedly spun to the negative because all of them have been on the table since the device was first presented for approval. The plan for commercialization has been shoddily analyzed by reporters and analysts alike. It is not only viable in that each unit can produce minimally 100K in revenue to perpetuity but also will be easy to launch to the market because it costs very little for the participating physician to lease one and the training time is minimal. The reasons behind this stock being so ridiculously cheap are a) the FDA's malfeasance and misinterpretation of the trial data. b) the completely misguided and shortsighted analysis, on all fronts, from all public channels whether they be analysts, reporters or otherwise. c)Blatant price manipulation that comes with low volume and a stock being in limbo.MELA is artificially cheap. Look for MELAfind to save hundreds if not thousands of lives and to absolutely annihilate the S+P for years to come.

Recs

0
Member Avatar fools4sail (< 20) Submitted: 9/8/2011 3:26:22 PM : Outperform Start Price: $33.80 MELA Score: -168.93

It was approved by the EU recently and I believe it is going to be FDA approved.

Recs

0
Member Avatar porsche108 (< 20) Submitted: 7/6/2011 11:11:13 PM : Outperform Start Price: $21.70 MELA Score: -146.46

If the F.D.A. would get on the ball peoples lives would be saved with Melafind!

Recs

0
Member Avatar Downeastah (< 20) Submitted: 6/19/2011 4:53:19 PM : Outperform Start Price: $24.80 MELA Score: -157.52

RELIABLE HELP ON A HIGHLY DANGEROUS DISEASE WOULD BE WELCOMED. NON-INVASIVE

Recs

0
Member Avatar Zatopek903MoT (28.57) Submitted: 11/19/2010 11:29:07 AM : Outperform Start Price: $49.50 MELA Score: -169.36

Now that science panel approved, albeit by narrowest of margins, odds of FDA approval much approved. Now's the time to buy (gamble?). Watch the shares skyrocket w/ approval. Put stop at down 10% in case MELA does not get FDA okay.

Recs

0
Member Avatar Maribaza (94.68) Submitted: 11/19/2010 10:59:16 AM : Underperform Start Price: $50.50 MELA Score: +169.53

37,11,16
3,7,6

Recs

0
Member Avatar greenhornet07 (< 20) Submitted: 11/11/2010 9:31:42 PM : Underperform Start Price: $58.70 MELA Score: +168.43

Liability is great for a missed cancer diagnosis. Doubt that technology will ever be that accurate to allow company to be viable in the long term.

Recs

1
Member Avatar JonPon (< 20) Submitted: 9/10/2010 11:13:32 AM : Outperform Start Price: $66.60 MELA Score: -183.21

With the accuracy of the MELAFind device being statistically significant in comparison with dermatologists and with it's non-invasive nature it is sure to be a winning device.

Recs

1
Member Avatar wkentward (31.30) Submitted: 8/20/2010 10:37:38 PM : Outperform Start Price: $67.80 MELA Score: -193.18

Superior technology; FDA Approval pending; phenomenal sales and earnings potential

Recs

0
Member Avatar jrusso9722 (< 20) Submitted: 7/22/2010 1:47:53 PM : Outperform Start Price: $65.80 MELA Score: -186.16

Since Mela-Find (r), is not a drug, I believe, FDA wonders what criteria to use to approve it. I'll predict FDA will approve it. How in God's name can they not approve an imaging device to identify the most deadly form of skin cancer. They dare not keep it from the public.

Recs

1
Member Avatar eric787 (68.54) Submitted: 6/29/2010 1:50:41 PM : Outperform Start Price: $83.10 MELA Score: -195.85

Everybody likes the sun

Recs

8
Member Avatar markofzorro (< 20) Submitted: 5/19/2010 12:52:29 PM : Underperform Start Price: $59.10 MELA Score: +182.52

Based on MELA's press release, it is unclear if MelaFind will find new cases of melanoma that dermatologists don't already suspect. MELA's study was done in people the dermatologists already suspected melanoma, not the general public.

It is not a screening test and won't be useful in testing the general population, since the test is false positive in about 90% of the people WITHOUT melanoma.

There may be an economic advantage if it is cheaper than biopsy in that it will avoid the need for ~5% of biopsies.

The bottom line is that the test may fill a small niche. If it isn't significantly cheaper than biopsies, Insurance companies are unlikely to pay for it in today's climate of cost cutting.

Details below for those with the stomach for them:
From the MELA Blurb at http://medicalphysicsweb.org/cws/article/newsfeed/37805:

“MelaFind detected 112 of 114 (98% sensitivity …”

Sensitivity is the proportion of people with melanoma who have a positive MelaFind test. A perfect test would be positive in 100%, and MelaFind is very, very good according to this data.

In practice, this means if you are a doctor and suspect somebody may have a melanoma, a positive test will increase your suspicion, and you will go on to biopsy and treatment -- perhaps earlier than if you weren’t sure and waited to see if the tumor grew before biopsy. If you have a NEGATIVE test, you can be pretty confident the patient doesn’t have melanoma, because pretty much everybody with melanoma will have a positive test.

“MelaFind's specificity, the ability to accurately rule out disease, was significantly superior (9.5%) to that of the study dermatologists (3.7%) … “

Sensitivity is the proportion of healthy people without melanoma who have a negative test. Again, in a perfect world, 100% of healthy people would have a negative MelaFind test. In fact only 9.5% of them have negative tests, and 90.5% have false positive tests. Still MELA’s test is about twice as good as an expert dermatologist (3.7%).

In practice, this means that if your patient has a POSITIVE test, they might have melanoma or they might just be part of the false positives in healthy people, so the only way to rule out melanoma is to go ahead and biopsy.
So the test is most useful when the doctor suspects melanoma, and the test is negative. Then he can reassure the patient and spare them a biopsy.

There is a trade off between sensitivity and specificity, if you make a test more sensitive, it is hard to make it more specific. Because melanoma is a devastating, life-threatening cancer, MELA chose to make the test very specific. This way nobody with cancer gets missed. The cost of an extra biopsy is relatively small both medically and financially.

Writing this little summary makes me wonder how useful this test will really be, since its primary utility will be for suspect patients with negative tests.

Recs

0
Member Avatar anne1730 (85.58) Submitted: 4/8/2010 7:05:44 PM : Outperform Start Price: $74.50 MELA Score: -171.50

Melanoma is still a diagnostic problem for Fam.
physicians & this test will bring patients in early stage for treatment

Recs

0
Member Avatar poppy9151 (< 20) Submitted: 3/22/2010 2:28:51 PM : Outperform Start Price: $92.00 MELA Score: -175.43

No Thanks about the article. I have had frequent bouts with skin cancer; probably because of my frequent exposure to the outdoors playing golf, swimming, yardwork and living in The Sunshine State. I think Mela will hit it out of the park.

Recs

0
Member Avatar billbu (97.87) Submitted: 3/10/2010 10:38:41 AM : Outperform Start Price: $66.40 MELA Score: -173.33

Promising technology that addresses a large and important health issue. Melanoma if not detected has a very low survivability. This company's product allows for detection comparable to the best experts in the field. FDA Approval is likely by Summer although there are significant challenges to successful commercialization.

Results 1 - 20 of 43 : 1 2 3 Next »

Featured Broker Partners


Advertisement